Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment

Real-World Assessment of Compl-AI in Predicting Early Discontinuation of Medication for Treatment of Opioid Use Disorder (MOUD) in Community and Specialty Treatment Programs

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07456930

Enrollment

295

Registered

2026-03-09

Start date

2026-06-01

Completion date

2026-12-01

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Keywords

Opioid Use Disorder

Brief summary

The goal of this observational study is to learn whether the Compl-AI model can accurately predict who is likely to stop their medication for opioid use disorder (MOUD) early in adults receiving real-world treatment for opioid use disorder (OUD). The main questions it aims to answer is: can the model accurately predict early discontinuation of MOUD? Because this study has no comparison groups, all participants receive their usual MOUD as part of routine care. Researchers will observe how participants engage with treatment and how well Compl-AI predicts their outcomes. Participants will complete 4 visits, including a questionnaire about personal experiences during first visit and questions about their substance use and treatment history. During the monthly study visits, the researchers will record in particular the attendance at MOUD medication visits, the medication adherence and any treatment discontinuation.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ability to understand and provide written informed consent. * Male and female participant 18 years of age at the time of consent. * Participant with OUD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). * Eligible to receive MOUD per site standard of care or currently receiving MOUD initiated prior to study enrollment.

Exclusion criteria

* Cognitive impairment that precludes the ability to provide written informed consent. * Already enrolled in another study/program.

Design outcomes

Primary

Measure	Time frame
Proportion of attended MOUD medication visits	Observation period will be three (3) months.
Proportion of prescribed doses taken	Observation period will be three (3) months.

Countries

United States

Contacts

CONTACTChantal Gossuin

chantal.gossuin@cognivia.com+32(0)71140200

CONTACTLaura Onckelinx

laura.onckelinx@cognivia.com+32(0)71140200

Outcome results